• small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7

Investors Overview

CORPORATE PROFILE

MiMedx® is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. “Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies are AmnioFix®, EpiFix® and CollaFix™. AmnioFix® and EpiFix® are our tissue technologies processed from human amniotic membrane derived from donated placentas. Through our donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx is the leading supplier of amniotic tissue, having supplied over 400,000 allografts to date for application in the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. CollaFix™, our next technology platform we plan to commercialize, is our collagen fiber technology, developed with our patented cross-linking polymers, designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair. CollaFix™ is the only biological, biodegradable, biomimetic technology that matches human tendon in strength and stiffness.
MIMEDX GROUP INC(Common Stock)
ExchangeNASDAQ CM (US Dollar)
Price$9.58
Change Stock is Up 0.27 (2.90%)
Volume876,887

09/02/15  4:00 p.m. ET

Minimum 20 minute delay
Stock chart for: MDXG.O.  Currently trading at $9.58 with a 52 week high of $13.20 and a 52 week low of $6.81.
Data Provided by Thomson Reuters

NEWS AND EVENTS

View All
Sep-02-2015
MiMedx Corrects A Second Inaccurate MTF Press ReleaseMARIETTA, Ga., Sept. 2, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to

Read More

Aug-27-2015
MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal BoardMARIETTA, Ga., Aug. 27, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to

Read More

Aug-26-2015
MiMedx Announces Publication Of Latest Scientific Study Demonstrating The Ability Of Its Allografts To Regulate Diabetic Stem CellsEPIFIX ALLOGRAFTS SHOWN TO BOTH STIMULATE AND PROMOTE PROLIFERATION OF STEM CELLS FROM DIABETIC DONORS MARIETTA, Ga., Aug. 26, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), th

Read More

RECEIEVE E-MAIL ALERTS

Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever MIMEDX GROUP INC posts new information to the site. Just enter your e-mail address and click Submit.
 

PRODUCTS

Products

CONTACT US

888.543.1917

Products

CONTACT US

888.543.1917